Antiviral activity of amides and carboxamides of quinolizidine alkaloid (−)-cytisine against human influenza virus A (H1N1) and parainfluenza virus type 3

References

• Abdullaev NP, Makhmudov US, Tashkhodzhaev B, Genzhemuratova G, Levkovich MG, Shakhidoyatov KM. 2009. Structural features of N-acylcytisines. Chem Nat Compd. 45(6):837–843.
   Web of Science ®Google Scholar
• Abed Y, Boivin G. 2006. Treatment of respiratory virus infections. Antivir Res. 70(2):1–16.
   PubMed Web of Science ®Google Scholar
• Alymova IV, Taylor G, Takimoto T, Lin TH, Chand P, Babu YS, Li C, Xiong X, Portner A. 2004. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother. 48(5):1495–1502.
   PubMed Web of Science ®Google Scholar
• Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin T-H, Hutchison TL, Elliott AJ, Parker CD, et al. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 43(19):3482–3486.
   PubMed Web of Science ®Google Scholar
• Barik S. 2012. New treatments for influenza. BMC Med. 10(1):104.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The protein data bank. Nucleic Acids Res. 28(1):235–242.
   PubMed Web of Science ®Google Scholar
• Boido CC, Sparatore F. 1999. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Farmaco. 54:438–451.
   PubMedGoogle Scholar
• Buckingham J. 2010. Dictionary of alkaloids. 2nd ed. Boca Raton, US. CRC Press.
   Google Scholar
• Cady SD, Schmidt-Rohr K, Wang J, Soto CS, DeGrado WF, Hong M. 2010. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature. 463(7281):689–692.
   PubMed Web of Science ®Google Scholar
• Denny FW, Clyde WA. Jr 1986. Acute lower respiratory infections in nonhospitalized children. J Pediatr. 108(5):635–646.
   PubMed Web of Science ®Google Scholar
• Dirr L, El-Deeb IM, Guillon P, Carroux CJ, Chavas LMG, von Itzstein M. 2015. The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed. Angew Chem Int Ed. 54(10):2936–2940.
   PubMed Web of Science ®Google Scholar
• Drozd DR, Limaye AP, Moss RB, Sanders RL, Hansen C, Edelman JD, Raghu G, Boeckh M, Rakita RM. 2013. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis. 15(1):e28–e32.
   PubMed Web of Science ®Google Scholar
• Dung Z, Jung K, Zhu L, Lai W, Xie H, Lee K-H, Huang L, Chen C-H. 2014. Identification and synthesis of quinolizidines with anti-influenza A virus activity. ACS Med Chem Lett. 5(8):942–946.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B: Phys Biol Sci. 93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. 2000. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol. 74:1108–1114.
   Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, et al. 2018. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 379(10):913–923.
   PubMed Web of Science ®Google Scholar
• Henrickson KJ. 2003. Parainfluenza viruses. Clin Microbiol Rev. 16(2):242–264.
   PubMed Web of Science ®Google Scholar
• Horimoto T, Kawaoka Y. 2005. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 3(8):591–600.
   PubMed Web of Science ®Google Scholar
• Ison MG. 2011. Antivirals and resistance: influenza virus. Curr Opin Virol. 1(6):563–573.
   PubMed Web of Science ®Google Scholar
• Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL. 2009. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine. 27(12):1848–1857.
   PubMed Web of Science ®Google Scholar
• Liu M-Y, Wang S, Yao W-F, Wu H-Z, Meng S-N, Wei M-J. 2009. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single or dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 31(4):784–792.
   PubMed Web of Science ®Google Scholar
• Moghadami M. 2017. A narrative review of influenza: a seasonal and pandemic disease. Iran J Med Sci. 42(1):2–13.
   PubMed Web of Science ®Google Scholar
• Moll F, Luputiu G. 1972. Harnstoff-derivate des cytisins. Arch Pharm Pharm Med Chem. 305(10):771–776.
   PubMed Web of Science ®Google Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Moradi M-T, Karimi A, Lorigooini Z. 2017. Alkaloids as the natural anti-influenza virus agents: a systematic review. Toxin Rev. 37(1):11–18.
   Web of Science ®Google Scholar
• Pan QM, Li YH, Hua J, Huang F-P, Wang H-S, Liang D. 2015. Antiviral matrine-type alkaloids from rhizomes of Sophora tonkinense. J Nat Prod. 78(7):1683–1688.
   PubMed Web of Science ®Google Scholar
• Rouden J, Ragot A, Gouault S, Cahard D, Plaquevent J-C, Lasne M-C. 2002. Regio- and diastereoselective functionalization of (-)-cytisine: an unusual N-C acyl migration. Tetrahedron-Asymmetr. 13(12):1299–1305.
   Google Scholar
• Shao W, Li X, Goraya MU, Wang S, Chen J-L. 2017. Evolution of influenza A virus by mutation and re-assortment. IJMS. 18(8):1650.
   Web of Science ®Google Scholar
• Tam RC, Lau JYN, Hong Z. 2002. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother. 12(5):261–272.
   Web of Science ®Google Scholar
• Tsypysheva I, Koval'skaya A, Petrova P, Lobov A, Borisevich S, Tsypyshev D, Fedorova V, Gorbunova E, Galochkina A, Zarubaev V. 2019. Diels-Alder adducts of 3-N-substituted derivatives of (−)-Cytisine as influenza A/H1N1 virus inhibitors; stereodifferentiation of antiviral properties and preliminary assessment of action mechanism. Tetrahedron. 75(21):2933–2943. doi:https://doi.org/10.1016/j.tet.2019.04.021.
   Web of Science ®Google Scholar
• Tsypysheva IP, Koval’skaya AV, Khalilova IU, Bakhtina YY, Khisamutdinova RY, Gabdrakhmanova SF, Lobov AN, Zarudii FS, Yunusov MS. 2014. New 12-N-β-hydroxyethylcytisine derivatives with potential antiarrhythmic activity. Chem Nat Compd. 50(2):333–336.
   Web of Science ®Google Scholar
• Tsypysheva IP, Koval′Skaya AV, Lobov AN, Salimgareeva MK, Fatkullina US, Petrova PR, Gabdrakhmanova SF, Makara NS, Suponitskii KY, Vakhitova YV, et al. 2013. Synthesis and neuropharmacological activity of N-1-adamantylcytisine-12-carbamide and its 12-thiocarbonyl analog. Chem Nat Compd. 49(4):707–711.
   Web of Science ®Google Scholar
• Tsypysheva IP, Koval’skaya AV, Makara NS, Lobov AN, Petrenko IA, Galkin EG, Sapozhnikova TA, Zarudii FS, Yunusov MS. 2012. Synthesis and specific nootropic activity of (-)-cytisine derivatives with carbamide and thiocarbamide moieties in their structure. Chem Nat Compd. 48(4):629–634.
   Web of Science ®Google Scholar
• Waghmare A, Wagner T, Andrews R, Smith S, Kuypers J, Boeckh M, Moss R, Englund JA. 2015. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatric Infect Dis Soc. 4(2):114–118.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, et al. 2017. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: An epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 17(8):822–832.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS, Taylor G, Xiong X, Yan X, Portner A, et al. 2009. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Antimicrob Agents Chemother. 53(9):3942–3951.
   PubMed Web of Science ®Google Scholar
• Webster RG, Monto AS, Braciale TJ, Lamb RA. 2013. Textbook of Influenza. 2nd ed. Oxford, UK: John Wiley & Sons.
   Google Scholar
• Weinberg GA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffin MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG. 2009. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr. 154(5):694–699.
   PubMed Web of Science ®Google Scholar